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Abstract
Introduction: Adherence to HIV antiretroviral therapy (ART) is a critical determinant of HIV-1 RNA viral suppression and health
outcomes. It is generally accepted that HIV-related stigma is correlated with factors that may undermine ART adherence, but its
relationship with ART adherence itself is not well established. We therefore undertook this review to systematically assess the
relationship between HIV-related stigma and ART adherence.
Methods: We searched nine electronic databases for published and unpublished literature, with no language restrictions. First
we screened the titles and abstracts for studies that potentially contained data on ART adherence. Then we reviewed the full text
of these studies to identify articles that reported data on the relationship between ART adherence and either HIV-related stigma
or serostatus disclosure. We used the method of meta-synthesis to summarize the findings from the qualitative studies.
Results: Our search protocol yielded 14,854 initial records. After eliminating duplicates and screening the titles and abstracts, we
retrieved the full text of 960 journal articles, dissertations and unpublished conference abstracts for review. We included
75 studies conducted among 26,715 HIV-positive persons living in 32 countries worldwide, with less representation of work from
Eastern Europe and Central Asia. Among the 34 qualitative studies, our meta-synthesis identified five distinct third-order labels
through an inductive process that we categorized as themes and organized in a conceptual model spanning intrapersonal,
interpersonal and structural levels. HIV-related stigma undermined ART adherence by compromising general psychological
processes, such as adaptive coping and social support. We also identified psychological processes specific to HIV-positive persons
driven by predominant stigmatizing attitudes and which undermined adherence, such as internalized stigma and concealment.
Adaptive coping and social support were critical determinants of participants’ ability to overcome the structural and economic
barriers associated with poverty in order to successfully adhere to ART. Among the 41 quantitative studies, 24 of 33
cross-sectional studies (71%) reported a positive finding between HIV stigma and ART non-adherence, while 6 of 7 longitudinal
studies (86%) reported a null finding (Pearson’s x27.7; p0.005).
Conclusions: We found that HIV-related stigma compromised participants’ abilities to successfully adhere to ART. Interventions
to reduce stigma should target multiple levels of influence (intrapersonal, interpersonal and structural) in order to have
maximum effectiveness on improving ART adherence.
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Introduction
Adherence to HIV antiretroviral therapy (ART) is a critical
determinant of HIV-1 RNA viral suppression and health
outcomes [13]. Early studies of ART adherence focused
primarily on cognitive processes that may affect adherence,
such as forgetfulness and health literacy [46]. More recently,
investigators have shown that ART adherence in resource-
limited settings, where treatment is generally provided free of
charge, may be contingent upon structural barriers, such as
food insecurity [712] or geographic isolation and lack of
resources to pay for transportation to clinic [1317].
The stigma of HIV and AIDS is one social process that has
been broadly assumed to adversely affect multiple facets of
engagement in HIV-related care as well as other factors that
may undermine ART adherence, including HIV serostatus
disclosure [1820], social support [18,21] and mental well-
being [21,22]. Goffman [23] conceptualized stigma as an
‘‘attribute that is deeply discrediting’’ imposed by society
that reduces someone ‘‘from a whole and usual person to a
tainted, discounted one’’ (p. 3). When the attribute becomes
linked to ‘‘discrediting dispositions’’ (e.g., negative evalua-
tions or stereotypes), these may come to be widely believed
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in the community [24]. During the labelling process [2527],
persons with and without the stigmatized attribute are
separated into ‘‘them’’ and ‘‘us’’ [28] and may be subjected
to overt acts of hostility and discrimination (enacted stigma)
[29]. To avoid the potentially unpleasant consequences of
revealing their discredited status, stigmatized persons may
elect to conceal their seropositivity from others [20,30].
Stigmatized persons may also internalize the beliefs held in
the community and develop self-defacing internal represen-
tations of themselves (internalized stigma)  possibly leading
to demoralization, diminished self-efficacy and emotional
distress [31,32].
Despite substantive advances in our understanding of
the stigma process, the mechanisms through which stigma
compromises ART adherence are not well understood. From
a public health perspective, this is an important gap in the
literature because sustained adherence [33] is a critical step
in the spectrum of engagement in HIV-related care [34,35].
Although the ‘‘test-and-treat’’ approach [36] has achieved a
great deal of popularity in a brief amount of time, observers
have expressed concerns that persisting stigma may pose a
major obstacle to its success [37]. Therefore, we undertook
this review to systematically assess the relationship between
HIV-related stigma and ART adherence.
Methods
Search strategy and study selection
Three study authors (AER, AGO, ACT) searched nine electronic
databases for published and unpublished literature: BIOSIS
Previews, the Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Embase, the Educational Resources
Information Center (ERIC), the Medical Literature Analysis
and Retrieval System Online (MEDLINE), ProQuest Disserta-
tions & Theses, PsycINFO, Web of Science (Science Citation
Index Expanded, Social Sciences Citation Index, and Arts &
Humanities Citation Index) and the World Health Organization
African Index Medicus. In general, each set of search terms
applied to these databases was oriented towards identifying
studies of ART adherence among HIV-positive adults (Box S1).
We conducted all searches in May 2011, with the exception of
the ProQuest search, which was performed in June 2011. In
February 2013, one study author (ACT) updated the MEDLINE
search to identify more recent articles published since the
study was initiated.We also consulted with experts in the field
to identify additional studies that our systematic evidence
search may have missed.
First we imported all records into EndNote reference
management software (version X4.0.2, Thomson Reuters,
Philadelphia, Penn.) and used the automated ‘‘Find Dupli-
cates’’ function to exclude any duplicates. Then we screened
the titles and abstracts of all records to identify studies that
appeared to be potentially related to ART adherence among
HIV-positive persons. We then obtained the full text of
these articles for review, specifically to identify articles
that reported either a quantitative estimate of association
between a measure of stigma or disclosure and a measure of
adherence, or qualitative findings about how stigma or lack
of disclosure affected adherence. Although our review was
focused on the relationship between stigma and adherence,
we also chose to include studies examining the impacts of
serostatus non-disclosure because it is a proximate conse-
quence of stigma [19,20]. Our goal in including qualitative
studies as part of this systematic review was to inductively
develop an in-depth understanding of persistent themes and
assess the transferability of these themes across contexts
[38]. Due to our interest in describing relationships between
stigma and adherence across a wide range of countries, we
chose not to exclude any study based on quality, country of
origin or language.
Quality assessment
To assess the quality of the included qualitative studies, we
adapted questions representing the three key conceptual
domains described in the Critical Appraisal Skills Programme
quality assessment tool [39,40]. These domains also mapped
onto prominent criteria employed by previous researchers as
identified in the review of qualitative quality assessment
tools by Tong et al. [41]. The criteria we used were as follows:
(1) the role of the researcher was clearly described; (2) the
sampling method was clearly described; (3) the method of
data collection was clearly described; and (4) the method
of analysis was clearly described. We found that the in-
cluded qualitative studies consistently described the role
of the research and the method of data collection, but
many studies reported neither the sampling method nor the
method of analysis. Overall, 15 studies were assessed to be
at low risk of bias (Table S1).
To assess the quality of the included quantitative studies,
we developed an assessment tool based on the six major
conceptual domains identified by Sanderson et al. [42]. The
criteria we used were as follows: (1) the study was based
on a probability sample of participants; (2) the study used a
validated self-report scale to measure stigma or disclosure;
(3) the study used a validated self-report scale or objective
count (e.g., pill count, pharmacy refill) to measure ART
adherence; (4) the statistical analysis accounts for missing-
ness at random (MAR) or missingness not at random (MNAR)
(longitudinal studies only); (5) the study design or statistical
analysis controls or adjusts for potential confounding; and (6)
competing interests were declared. Overall, all studies except
for one were assessed to be at risk of bias (Table S2).
Data synthesis
We organized studies by year of publication, country of
origin, study design and types of measures employed. For the
quantitative studies, due to substantial heterogeneity in the
measures of stigma, serostatus disclosure and ART adherence
that were employed, we did not attempt to summarize the
data using meta-analysis. However, we examined patterns
across studies with respect to the estimated associations and
the precision of these estimates.
For the subset of qualitative studies, our goal was to
generate new theoretical insights. Therefore, we used the
iterative process of meta-synthesis proposed by Noblit and
Hare [43] to identify themes that recurred frequently or were
prominently featured throughout the data. Meta-synthesis
(also described as meta-ethnography) is an interpretive
approach to summarizing qualitative research that has been
employed to understand vaginal practices in sub-Saharan
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Africa [44], delays in presentation for cancer care [45] and
adherence to tuberculosis treatment [46]. Key themes and
concepts were collected and peer-reviewed for inclusive-
ness. First-order findings (quotations) were used to support
second-order interpretations (authors’ analyses) to gain
new insight into the relationships between stigma and ART
adherence. A summary definition of second-order constructs
was generated for further clarification and then consolidated
into a line of argument that led to a third-order analysis,
which we describe below. Based upon the data set, we
achieved theoretical saturation within the first 10 manu-
scripts, although basic elements for meta-themes were
evident as early as six manuscripts. Variability within the
data followed similar patterns, consistent with prior qualita-
tive meta-synthesis research [47].
Results
Our initial search yielded 14,854 records, of which 9009 were
identified as duplicates through the use of automated
software (Figure 1). After screening the titles and abstracts
of the remaining 5845 records, we eliminated 4000 records
that did not appear to contain relevant data on adherence or
provided potentially relevant adherence data specific to a
specialized population (e.g., children or pregnant women),
eight unpublished conference abstracts or dissertations
matched to subsequently published peer-reviewed journal
articles in our database of records, 199 reviews that did not
report original data, and 678 additional duplicates that
had been misclassified as non-duplicates by the automated
software. We retrieved 960 journal articles, unpublished
dissertations and conference abstracts for full text review.
Of these, 889 did not contain quantitative or qualitative data
relating stigma or disclosure to ART adherence and were
therefore excluded. Expert review suggested four additional
articles for inclusion. The final sample included 75 studies:
34 qualitative studies and 41 quantitative studies.
Synthesis of qualitative studies
Thirty-four qualitative studies conducted during 19992013
were included in the review, including one written in French.
Initial search, May 2011
13917 Records identified
through database
searching  
9009 Duplicate
records
excluded   
4908 Titles and abstracts
screened 
4095 Excluded
813 Full text reports
assessed for
eligibility  
Full text reports
assessed for
eligibility  
760 Excluded
75
Additional articles
4 Identified through
expert review 
Articles included in 
review
Updated search, Feb 2013
937 Records identified
through database
searching  
790 Excluded
147
129 Excluded
Figure 1. Flow diagram. We identified 14,854 records by searching nine electronic databases, yielding 34 qualitative studies and 41
quantitative studies.
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Represented in these manuscripts were views from 1328
study participants in 26 countries. Of note, only one country
from the UNAIDS Eastern Europe and Central Asia region was
represented: Serbia and Montenegro. The median number
of participants was 38 (interquartile range (IQR), 27 to 48;
range, 6 to 118). Participants included adult men and women
ranging in age from 18 years to over 60 years old, HIV-
positive persons as well as providers of HIV care, single
persons and those in intimate partnerships, and persons with
and without children. Specific high-risk groups were well
represented and included men who have sex with men,
injection drug users and commercial sex workers.
After reviewing each of the qualitative studies in detail, we
identified 24 second-order constructs, supported by original
quotes, in multiple manuscripts. Second-order constructs
relevant to ART adherence were identified, and key themes
were generated into a line of argument that led to 15 third-
order constructs. These were grouped into five distinct
third-order labels that we categorized as themes, all of
which are described in detail in Table 1.
Theme 1: social support
The most commonly cited theme related to ART adherence
was the role of social support. Specifically, participants
described spousal or familial support as being critical for
enabling them to overcome enactments of HIV-related
stigma and other obstacles to care and successfully adhere
to treatment [4870]. As noted by one 45 year-old HIV-
positive rice dealer in Chennai, India,
A person without a family is like a single tree
struggling for life. My children and my wife are my
backbone. Now I have brought changes in myself
and want to achieve many things. [54, p. 496]
Compromised relationships could result from either HIV
illness or HIV treatment. Many participants described being
socially isolated due to the physical manifestations of
HIV-related illness [5557,6467,69,71,72]. As described by
one HIV-positive mother in Kampala, Uganda,
These days when people come to know that you
have AIDS they don’t want to come near you, as if
you are an abominable thing (‘bakwenyinyala’). You
cannot feel free. Wherever you go they start talking,
‘See that one, she is sick’. [57, p. S88]
On the other hand, HIV treatment could also undermine social
relationships. Unintended disclosure was viewed as a con-
sequence of being on complex regimens that often needed
to be taken multiple times per day [12,52,53,55,5961,63
65,69,7274]. This was commonly discussed in some of the
older studies, which were conducted during a time when
pill burden was high and participants reported difficulty in
understanding when and how to take their medications
[12,50,52,58,60,61,64,67,68,70,74,75]. Attempts at conceal-
ment, such as by hiding medications or furtively taking
medications, were described as contributing to treatment
interruptions [12,48,49,5456,6472,76,77].
In addition, some participants felt that the medica-
tions themselves were associated with side effects that had
unwelcome physical manifestations:
[ART] has given more side-effects for me such as
vomiting, herpes/zoster, and skin rashes. I have lost
my sight in my right eye and my left eye also has
poor vision.
 HIV-positive woman from far western Nepal
[68, p. 7]
Desire to avoid these physical stigmas, or fear of ‘‘the thing
[sic] that people would say’’ [55, p. 102], motivated some
participants to avoid taking medications and evade detection.
A more circumscribed discussion in the literature related
to norms about gender roles, particularly in patriarchal cul-
tures. Byakika-Tusiime et al. [57] explained how HIV-positive
women were better able to adhere to ART when others
did not identify them as being infected with HIV. An HIV-
positive mother could evade detection by giving birth to an
uninfected child and establishing her role as a caretaker.
This was discussed by an HIV-positive mother in Kampala,
Uganda, who described how giving birth to a healthy baby
changed her family’s assumptions about the inevitability of
her death:
When [my sister] saw that since giving birth, my
baby was not falling sick (the other children used to
be sickly), that my baby was looking nice, did not
have a rash, and was growing fast she said ‘I used to
think you were infected. I had taken you out of all
my plans.’ I responded that ‘I am not infected, don’t
you see my baby?’ So that’s where I ended her
suspicions about my being sick. Now she knows that
I am not infected, which is not true. [57, p. S88]
Other authors mentioned the importance of women being
able to hide their seropositivity in settings where men
dominated household decision-making, so as to avoid
social isolation and/or abandonment [49,52,54,64,68,72].
In these settings, some women reported relying on health-
care providers to inform their sexual partners of their
HIV status rather than informing their partners directly
themselves.
Women who gave birth to an HIV-positive child experien-
ced feelings of shame and social rejection, both within
and outside of the family. Participants in these studies
discussed the difficulty associated with disclosing the
status of an HIV-positive child, particularly in communities
where HIV was highly stigmatized and where appearing ill
often led to abandonment by one’s family and community
[48,53,5557,6467,69,71,72].
The thing that disturbs me is that I always think
what will I tell my child when he grows to a level of
understanding and he asks me why he is taking
drugs. Because even now he asks me, ‘Mummy, I no
longer cough but why am I still taking drugs every
day?’ What will I tell the child?’
 HIV-positive mother from Kampala, Uganda
[57, p. S88]
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Table 1. Qualitative studies on stigma, disclosure and ART adherence (N34)
Third-order
labels
Third-order
constructs Second-order constructs Summary definition First-order constructs Source(s)
Social support Intimate and
familial
relationships
Spousal, peer and familial
support
Participants discussed support from
spouses, peers and family as critical for
overcoming stigma and maintaining
adherence, as was having a sense of
obligation to family
Well, they encourage me, like my folks have
[said] ‘you took your medication today?’
[55, p. 5]
I am thankful to God for giving me such
a good husband. He takes care of me well.
I have given him a lot of trouble. He has
spent so much money for my treatment.
[54, p. 496]
[4870,78,79]
Context of male-dominated
household decision-making
In cultures where men are typically heads of
their households, women fear disclosing
their serostatus as they fear social isolation
and abandonment. Women may choose to
have providers give the test information to
their husbands by bringing them in for
testing. In addition, in some cultures,
women cannot travel alone to clinic to pick
up their medications.
[After testing positive] I went back home and
first kept quiet for two days. I asked myself,
how can I approach him to tell him? One day
when he came back, I told him, they checked
my blood but they refused to give me the
results until I take my spouse in for testing.
I convinced him and he accompanied me.
[57, p. S88]
[49,52,54,57,64,68,72]
Healthy children reducing
stigma
Clinical response to ART in children of
HIV-positive mothers reduces stigma and
often re-establishes mother’s role in family
Then when she saw that since giving birth, my
baby was not falling sick (the other children
used to be sickly), that my baby was looking
nice, did not have a rash, and was growing fast
she said ‘I used to think you were infected.
I had taken you out of all of my plans.’
I responded that, ‘I am not infected, don’t you
see my baby?’ So that’s where I ended her
suspicions about my being sick. Now she knows
that I am not infected, which is not true.
[57, p. S88]
[57]
Compromised
relationships
Physical manifestations of
HIV and AIDS leads to social
isolation
Physical signs of ill health may lead to
abandonment or to the belief that the
HIV-positive person is already dead
These days when people come to know that
you have AIDS they don’t want to come near
you, as if you are an abominable thing
(‘bakwenyinyala’). You cannot feel free.
Wherever you go they start talking, ‘See that
one, she is sick.’ [57, p. S88])
[5557,6467,69,71,72]
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Table 1 (Continued )
Third-order
labels
Third-order
constructs Second-order constructs Summary definition First-order constructs Source(s)
Complex regimens with
large numbers of
medications
Complex regimens characterized by a large
pill burden that required undesired
disclosure in order to adhere
. . . things got messed up, like my schedule,
wherever you go, you got to bring the medicine
pack, it’s even upsetting to open a bunch of
medicines. [53, p. 3]
Our guests were at my home; I didn’t feel
comfortable pulling out my drug boxes, then
I forgot and missed my drugs. [74, p. 467]
[12,52,53,55,5961,6365,69,7274]
Social rejection Participants adopted strategies of
concealment because they feared ridicule or
discrimination if they disclosed their HIV
status or if they were seen taking their
medications
My company made it hard. You know, because
I felt like I had to hide my medicine, you know?
All, you know, for shame. [55, p. 5]
Ordinary public thinks that if they mingle along
with the patient means they will get HIV.
[48, p. 532]
[12,48,49,5456,59,6472,76,77]
Treatment side-effects Observable side-effects of medications (e.g.,
dysmorphic body changes) carried stigma
It wasn’t hard for me to take my medicines; it
was the things that people would say . . .
[55, p. 5]
The medications compounded the way I felt,
how badly I felt, but I kept taking them because
I knew it was temporary. [74, p. 466]
[12,53,55,56,60,61,6366,68,71,73,
74,76]
Negotiating
disclosure to a
child
Stigma associated with a
child’s HIV status
Maternal shame and stigma related to
perinatal acquisition of HIV kept them from
informing HIV-positive children about their
seropositivity, with attendant challenges in
ART adherence
The thing that disturbs me is that I always think
what will I tell my child when he
grows to a level of understanding and
he asks me why he is taking drugs.
Because even now he asks me, ‘Mummy
I no longer cough but why am I still taking
drugs every day?’ What will I tell the child?’
[57, p. S88]
[48,53,57,64]
Self-Identity Race/minority
status
Outsider status based on
race
HIV-positive persons who belonged to racial
minority groups felt further stigmatized and
socially isolated
[49,55]
Sexual
orientation/
relationship status
Impact of social norms on
stigma and willingness to
disclose
Social norms further stigmatized
HIV-positive persons if the mode of
acquisition was not regarded as socially
acceptable behavior
In the gay community, I can’t go to somebody
and say, ‘I’m HIV.’ People avoid the subject. They
do not disclose it. [51, p. 906]
[50,51,54,6163,7174,76,77]
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Table 1 (Continued )
Third-order
labels
Third-order
constructs Second-order constructs Summary definition First-order constructs Source(s)
Substance abuse Social marginalization of
injection drug use
intensified for HIV-positive
users
Participants who actively used illicit
substances discussed being unable to
establish relationships with HIV-negative
persons or non-injection drug users, and
feeling socially isolated
Drug users, it’s a group that right now everyone
in society hates. Including myself,
I hate myself. But the problem is [that] there is
nothing I can do. [77, p. 1244]
[51,77]
Redefining
healthy living
Self-perception as
pro-active/choosing to be
healthy
Participants described knowing friends who
died from AIDS and not wanting to be like
them; the notion of ‘‘choosing to live’’
[74, p. 466]
Then I had some friends die of full-blown AIDS,
and I looked around and seen what a horrible
death that was . . . And so I know I wanted to
live, and I wouldn’t want to send my family
through that. So I knew I had to take my
medicine. [55, p .4]
I didn’t want to start drugs, but I had seen two
AIDS patients dead. They hadn’t used drugs.
[74, p. 466]
[5256,58,59,61,66,70,7274]
Acceptance of
status
Self-identifying as someone
who is HIV-positive
Participants who had accepted their status
found it easier to adhere vs. those who had
difficulty taking medications because it
reminded them of their seropositivity
The thing is it’s my life, you know. I don’t see it
much if somebody comes to me and tells me
that, ‘you’ve got HIV  you are HIV’. I don’t
have a problem with that because that’s
not his problem, that’s my problem you
know. As long as I know how I manage
it, I don’t give a damn about any other
person. [56, p. 303]
[50,56,67,69,70,73,74]
Poverty Economic
implications of
HIV
Mutually reinforcing
relationship between
poverty and stigma
HIV-related illness and perceived economic
inadequacy leading to social exclusion
They see it as useless to assist someone who
has a shorter time to live. It’s like wasting
money. Why assist someone who is going to
die? [67, p. 1311]
There is no need to waste any more money on
her, give me this lady and I will put her in the
car and take her to her rural home with her
children. [72, p. 875]
With ART, I have returned to work and earn
money; friends who avoided me in the past are
now more accepting of me . . . If I do not take
this medicine as I am told, I will get sick and
[54,56,67,72]
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Table 1 (Continued )
Third-order
labels
Third-order
constructs Second-order constructs Summary definition First-order constructs Source(s)
won’t be able to work again. People will also
begin to avoid me again. [72, p. 877]
Economic insecurity resulting from
HIV-related stigma
‘‘I thought that people would know my
HIV status when I have illnesses regularly
and am out of the office several times.’’
[67, p. 1311]
[54,67,72]
Costs associated with
treatment
Costs associated with purchasing
medications or with travel to the treatment
centre (along with loss of wages) made even
free ART prohibitively expensive for some,
leading to treatment interruptions
Even if I go for work I get Rs 100 in which 60
goes for tablets. So in the rest I have to manage
the other expenses, which is very difficult.
Medicines for HIV infection should be like other
general medicines where everyone can afford
to buy. Now I am not sure I can continue the
treatment for a long time.
[48, p. 529]
[12,48,54,60,61,64,67,68,70,72,76,77]
Coping Maladaptive
strategies
Anger at diagnosis Inability to accept diagnosis and anger at
diagnosis, with associated inability to
engage in HIV care and adhere to ART
I was mad, and I was upset, and I was in denial.
And it took me five years to tell anybody that
was close to me. So I kept that to myself for a
long time, and I was very angry. Right now, I
still don’t take [the medicines] like I should. [55,
p. 4]
[55,72]
Substance use and abuse Consumption of alcohol and use of drugs
provided a temporary refuge but also made
ART adherence more difficult
. . . I began to skip the medication. I said to
myself, ‘Well, today I’m not taking it, ‘cause I’m
gonna party . . . [drink] Come on, I was born to
party . . . [53, p. 3]
[52,53,59,73,78]
Fear that drugs are
dangerous and/or that HIV
is a curse fuelled by stigma
Participants expressed concerns about
taking medications feared to be dangerous
or toxic
Rural people do still not believe this medicine
[ART] works for HIV patients. HIV people will
die eventually either taking or not taking ART.
Why should I die by taking these malicious
pills? [68, p. 3]
[12,68,71,72]
Acceptance Knowledge that taking
medications will provide
benefits
Acceptance of the diagnosis counter-
balanced stigma, as participants described
moving on a continuum from willingness to
take medications, to engagement in
pro-active healthy lifestyle changes
This is your own responsibility. You know what
you got. You know you got medicine to take. No
matter what nobody else say or how peoples
feel about it, you got to take care of yourself
first. [55, p. 4]
[5456,58,59,66,67,69,70,7274]
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Table 1 (Continued )
Third-order
labels
Third-order
constructs Second-order constructs Summary definition First-order constructs Source(s)
During [the] last 5 years, taking medications
showed me its benefits. My CD4 cells [sic] count
was 80, with high viral loads, but now
I am okay. They actually helped and gave me
more longevity. [74, p. 467]
Mental wellbeing Treatment of depression
and anxiety related to
diagnosis
Treatment of depression resulting from HIV
diagnosis could ameliorate stigma and social
isolation
[49,57,65,67,69,72,73,77]
Morality and
spirituality
Notion of God’s will Participants discussed relinquishing control
of their lives to God and putting their faith
in a higher power to help them overcome
adversity
I just want to be a living witness, that God has
all power. He can do all things, and I put my
faith and trust in Him. [55, p. 45]
I believe in the power of prayers  I believe in
my church. It’s got hope for me . . . because
I have a feeling that God loves us . . . God is the
person that gave you that disease, and God is
the person who can take it out from you . . . You
have to have faith in that. [56, p. 305]
[12,52,5456,61,67,69,72]
Health systems Importance
placed in clinical
support staff
Nursing and physician
support to gain trust and
overcome social isolation
associated with stigma
Programs supporting social support and
building trust with the adherence nurse or
doctor were described as essential for
people who reported stigma as a barrier to
ART adherence
I felt so alone. It’s nice to know that somebody
does understand what it is all about and you
can depend on that person. [75, p. 117]
I trust the doctors and nurses. Therefore
I started the drugs. [74, p. 466]
[50,55,5860,62,63,67,69,70,72
75,80]
Support in designing
tolerable combination of
medications that are easily
available
Participants felt it was easiest to adhere if they
were on tolerable medications and if
providers were available in the event of
adverse side effects vs. those who feared
taking medications because of potential side
effects or complications. It was also important
to ensure that there were no stock-outs and
that medications were easily available.
I didn’t know the advantages of medications,
I feared the complications; therefore, I started
it very late. Actually, it was [a] wasting of my
time. [74, p. 466]
We can’t have any plan, because we don’t
know when supplies will fail. Some people can
get medicine and some can’t. [80, p. 317]
[55,5860,73,74,80]
Family-driven
treatment
Establishing treatment for
all members of the
household
Treatment to all HIV-positive members of a
family (including spouse and children)
provided support to overcome stigma and
improve medication adherence
[54,57]
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Theme 2: self-identity
Self-identity was another prominent theme identified in
these studies. Multiple studies elaborated on how social
norms intensified the stigma of HIV and undercut partici-
pants’ willingness to disclose to others [50,51,54,6163,71
74,76,77]. In many settings, study participants described HIV-
related stigma as being layered on top of pre-existing
inequalities, such as those related to gender, race or sexual
minority status:
I often hear my friends speak negatively about
people being HIV-positive. They always have degrad-
ing or negative remarks to make. What I dislike most
is when they call people names (e.g., fagot, whore,
and junkie). Whenever I go out with them or they
come over to visit, I don’t take my medications.
I could never let them know I’m positive.
 HIV-positive African-American woman living in
Baltimore, U.S. [49, p. 684]
Konkle-Parker et al. [55] and Edwards [49] both discussed
the difficulty that persons in a minority group experienced
when self-identifying as HIV-positive, since it often led to
further enactments of stigma, including overt discrimination
and/or acts of hostility. In such a setting (and consistent
with Theme 1), many participants opted not to take their
medications for fear of disclosure. Ware et al. [51] and Sabin
et al. [77] described the added burden and social isolation
that accompanied an HIV diagnosis among participants who
actively used illicit substances. In these cases, self-efficacy
was often low, and the lifestyle modifications required to
achieve consistent adherence proved to be challenging for
participants.
Drug users, it’s a group that right now everyone in
society hates. Including myself, I hate myself. But the
problem is [that] there is nothing I can do.
 40-year-old, injection drug using, HIV-positive
married man living in Old Dali, Yunnan Province,
China [77, p. 1244]
The experiences of persons who had internalized the stigma of
HIV was contrasted with reports of persons who had accepted
their HIV status and who had successfully cultivated a self-
perception of being pro-active and ‘‘choosing to live’’ [74, p.
466]. These participants were able to successfully adhere to
their ART regimens [5256,58,59,61,66,7274]. In these
studies, participants described how the deaths of HIV-
positive friends motivated them to take responsibility for
their own treatment. Some participants also described feeling
strong enough to continue to work and provide for their
families.
Then I had some friends die of full-blown AIDS,
and I looked around and seen what a horrible death
that was . . . And so I know I wanted to live, and
I wouldn’t want to send my family through that. So
I knew I had to take my medicine and . . . I know I
wants to live
 HIV-positive African-American study participant
from Mississippi [55, p. 4]
Theme 3: poverty
In several studies, participants also described how poverty
and stigma were intertwined in a reciprocal and mutually
reinforcing relationship (Figure 2). Participants spoke of being
viewed as weak, unproductive members of society and of
being excluded from informal networks of mutual aid:
They see it as useless to assist someone who has a
shorter time to live. It’s like wasting money. Why
assist someone who is going to die?
 HIV-positive person living in Dar es Salaam,
Tanzania [67, p. 1311]
Thus, conditions of poverty worsened stigma by emphasizing
one’s economic worth (or lack thereof) to the community. In
resource-limited settings where social networks serve as a
form of informal risk-sharing (consistent with Theme 1), and
where neighbours often live in close proximity to each other,
participants reported feeling ashamed and ultimately more
stigmatized by the public nature of unwanted disclosures:
I used to have a neighbour . . . who knew my status.
At times, I used to get porridge from KENWA and
bring it home. She had a child who was my kid’s
friend and age mate. One day, I gave the porridge
to her child and [she] was furious and shouted at
the little girl; ‘where did you get that porridge?
Take it back! You are taking porridge from people
with AIDS,’ she was shouting outside and I was in the
house.
 HIV-positive woman living in a slum community
in Nairobi, Kenya [72, p. 874]
Conversely, stigma was also found to exacerbate the eco-
nomic impacts of HIV. Economic insecurity resulting from
stigma and social isolation was particularly challenging for
widowed women who had lost their husbands to AIDS.
Tarakeshwar et al. [54] described 9 out of 10 widowed
women living in Chennai, India, who were discriminated
against, experienced housing insecurity and were isolated by
their in-laws after their husbands’ deaths. Stigma was also
cited as leading to embarrassment at work, and ultimately
causing participants to stop working in order to avoid
disclosure, leading to further economic insecurity:
I was on 5 days leave [when I came to test for HIV]
and I stayed another week. They were looking for
me at work . . . I was staying [away] because I was
Illness Economic Inadequacy
Exclusion
Stigma Exclusion
Food and
Livelihood
Insecurity  
Figure 2. Reciprocal relationships between poverty and stigma.
HIV-associated illness reinforces the perceived economic inadequacy
of HIV-positive persons, who are excluded from networks of mutual
aid. Stigmatized persons are excluded from the community, under-
mining their social support and worsening economic insecurity.
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sort of embarrassed by my own things. I was
embarrassed by my own fate.
 39-year-old HIV-positive unmarried man living
in Gaborone, Botswana [56, p. 304]
Lastly, for participants in resource-limited settings, financial
burdens posed a significant barrier to adherence due to costs
of the medications themselves, the costs of transportation to
pick up free medications from clinic, or wages foregone when
attending clinic [12,48,54,60,61,64,67,68,70,72,76,77]. These
treatment interruptions further compromised participants’
health, reinforcing their status as unproductive members of
the community.
Theme 4: coping
Coping emerged as a means by which participants attempted
to manage stigma and adhere to ART. At times, these coping
strategies were maladaptive and detrimental to health. Many
participants reported low self-esteem, depressed mood or
anger related to their diagnosis, citing their inability to cope
with their HIV status as the reason they failed to take their
medications [49,55,57,65,67,69,72,73,77]:
I was mad, and I was upset, and I was in denial. And
it took me five years to tell anybody that was close
to me. So I kept that to myself for a long time, and
I was very angry. Right now, I still don’t take [the
medicines] like I should.
 HIV-positive study participant recruited from a
large public infectious disease clinic in Mississippi
[55, p. 4]
In addition, ART misconceptions (e.g., ‘‘Why should I die by
taking these malicious pills?’’[68, p. 3]) and HIV conspiracy
beliefs that were often fuelled by stigma led to ART non-
adherence [12,68,71,72]. Participants who lacked the in-
ternal resources to cope adaptively described how they
self-medicated with alcohol or illicit substances, but these
behaviours further compromised their abilities to consistently
adhere to treatment [52,53,73].
Adaptive coping strategies included those that supported
adequate treatment for depression and anxiety, along with
acceptance of one’s diagnosis. These strategies appeared to
provide a protective buffer against stigma and promote
acceptance of lifelong treatment [12,5456,58,61,67,69,
7274], particularly for those who were able to incorporate
these into their new self-identities (consistent with Theme 2).
Likewise, spirituality and faith in God enabled some partici-
pants to overcome adversity associated with disclosure and
HIV-related stigma and to consistently take their medications
[12,52,5456,61,67,69,72]:
I am a Christian and a believer, I know that God
exists but those medicines also were inspired by
God. God is the one who gave inspiration to doctors
to make those medicines for us.
 59-year-old man on ART, from the Democratic
Republic of Congo [12, p. 4]
Theme 5: health systems
A theme common to several studies was that different
aspects of the health system could help to moderate the
impacts of HIV-related stigma on ART adherence. Specifically,
compassionate human capital elements could establish a
supportive clinical environment for patients, while certain
clinical programs could be designed to address care for the
entire family. As noted by one HIV-positive participant in
Connecticut,
[The nurses] take care of me, I love the people, they
go to your home, like they’re my friends. Every time
they say, how are you doing? Do you need anything?
[75, p. 117].
Doctors and nurses engaged in patient-centred care could
help to establish bonds of trust and empower patients to
overcome the stigma associated with taking medications
[50,55,60,62,63,6770,7275,80]. Some participants de-
scribed how medication regimens optimized for toler-
ability, with the fewest side effects and lowest pill burden,
allowed them to minimize the possibility that others in
the community might recognize their HIV status; this, in
turn, decreased stigma and increased participants’ chances
of successfully adhering to treatment [55,58,60,73,74,80].
Lastly, family-driven treatment programs designed to bring all
HIV-positive members of the family into care were thought of
as cultivating greater social support, reducing stigma and
improving ART adherence [54,57].
Synthesis of quantitative studies
Data from the quantitative studies were consistent with
these lines of inquiry. Our systematic search protocol
identified 34 cross-sectional and seven longitudinal studies
conducted between 1997 and 2009 that examined the
association between either stigma or disclosure and ART
adherence (Table 2). These studies included data from 25,387
participants living in 18 different countries, with the largest
proportion of studies (15/41 (37%)) based on data collected
in the United States. The median number of participants was
300 (IQR, 201439; range, 655760). Twenty-three studies
(56%) measured HIV-related stigma, while 21 studies (51%)
measured disclosure of seropositivity and three studies (7%)
included a measure of both. Most of the studies examin-
ing the effect of HIV-related stigma (18/23 (78%)) on ART
adherence employed a scale for which some evidence of
reliability and/or validity had previously been obtained. In
five studies, a multifactor scale was used (28%), while in
others specific aspects of HIV-related stigma were measured,
including enacted stigma (2/18 (11%)), disclosure concerns
(3/18 (16%)), perceived stigma (3/18 (16%)) and internalized
stigma (11/18 (61%)) (total percentage exceeds 100% as
some studies administered more than one scale). Of the 18
studies that used a formal scale for measuring stigma, only
three studies (17%) were conducted in a sub-Saharan African
setting, and each of these used a newly developed stigma
scale. The most widely used scale, administered in six studies,
was the four-factor HIV Stigma Scale developed by Berger
et al. [81]. To measure ART adherence, most studies used
self-report (30/41 (73%)). Of these, slightly more than half
(16/30 (53%)) employed a scale with previously demon-
strated evidence of reliability or validity; the AIDS Clinical
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Table 2. Studies reporting a quantitative measure of association between stigma or disclosure and ART adherence (N41)
Citation Study design and population
Study
period
Primary stigma or
disclosure measure Primary adherence measure Findings
Birbeck et al. [82] Cross-sectional study of 255 outpatients
from 3 clinics in rural Zambia
200506 Disclosure of HIV seropositivity to
spouse, family, friend, or no one
‘‘Good adherence’’ was defined as (a)
attendance at all ART clinic visits, (b) no
lapse in drug collection, and (c) no clinic
documentation indicating adherence
problems
Of those who had not disclosed to anyone,
only 17% had good adherence, whereas
5066% of those who had disclosed to a
spouse, family member or friend had good
adherence (p0.047)
Adeyemi et al. [83] Cross-sectional study of 320 outpatients
on ART for at least 12 months, recruited
in 2 cities in Nigeria
2009 Unclear measure (‘‘stigma and
discrimination’’)
Greater than one week delay in ART refill,
as determined by comparison of date of
scheduled appointment and date of actual
refill
‘‘Stigma and discrimination’’ was
associated with increased odds of delayed
ART refill (AOR1.4; 95% CI1.11.7),
after adjusting for distance to clinic and
occupation
Boyer et al. [84] Cross-sectional study of 2381 inpatients
in 27 national, provincial and district
hospitals throughout Cameroon
200607 Personal experience of HIV-related
stigma from partner or close family
members
Self-reported ART adherence based on a
14-item scale related to dose-taking and
dosing schedule [85], with ‘‘non-
adherent’’ persons defined as those who
had takenB100% of prescribed doses in
the past four weeks but did not report any
treatment interruptions lasting2
consecutive days
Experience of discriminatory behaviours
was associated with increased odds of
non-adherence (AOR1.74, 95%
CI1.142.65), after adjusting for
household income, binge drinking, food
insecurity, social support and healthcare
supply-related factors
Cardarelli et al. [86] Cross-sectional study of 103 outpatients
at a preventive medicine clinic for
low-income persons in Texas
2008a 40-item HIV stigma scale [81] Non-adherence was defined as a positive
screen on the simplified medication
adherence questionnaire, a modified
version of the Morisky scale, which
contains 6 items related to forgetfulness
or carelessness about ART dose taking
behavior [87,88]
The stigma score did not have a
statistically significant association with
non-adherence (AOR1.01; 95%
CI0.981.03), after adjusting for race,
education, racial discrimination, social
support, perceived stress or sense of
control
Carlucci et al. [89] Cross-sectional study of 424 outpatients
at a mission hospital in rural Zambia
2006 Single-item question about perceived
stigma
Pill count adherence measured over a
median of 84 days (interquartile range,
5698 days), with optimal adherence
defined as]95% doses taken
Perceived stigma did not have a
statistically significant association with
adherence (AOR1.1; 95% CI0.55-2.1),
after adjusting for travel time and
transportation cost
Charurat et al. [90] Cross-sectional study of 5760 persons
initiating ART at five university teaching
hospitals in urban Nigeria
200506 HIV disclosure to spouse or family
members
Pharmacy refill adherence rate (days of
medication dispensed divided by days
between visits), with poor refill adherence
defined asB95% adherence
Disclosure was associated with decreased
odds of low adherence (AOR0.85; 95%
CI0.750.97), after adjusting for
education, employment, distance to clinic
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Table 2 (Continued )
Citation Study design and population
Study
period
Primary stigma or
disclosure measure Primary adherence measure Findings
and time on ART. There was no univariable
association with loss to follow up
(OR0.96; 95% CI0.821.12)
Colbert [91] Cross-sectional analysis of baseline data
on 335 persons participating in a 5-year
randomized clinical trial conducted in
clinics and HIV service organizations in
western Pennsylvania and northeast
Ohio
200307 40-item HIV stigma scale [81] 30-day adherence as measured with
electronic event monitoring, with poor
adherence defined asB85% adherence
Neither personalized stigma (AOR0.98;
95% CI0.95-1.02) nor negative self-image
(AOR1.00; 95% CI0.941.06) had a
statistically significant association with poor
adherence, after adjusting for mental
health, self-efficacy and health literacy
Diiorio et al. [92] Cross sectional study of 236 outpatients
(32% women) from an HIV clinic in
Atlanta
200103 Four items related to internalized
stigma from the Perceived Stigma of
HIV and AIDS Scale [93]
Five items related to logistical adherence
barriers from the ACTG Adherence
Instrument [94]
In a structural equation model, stigma had
an indirect negative association with
adherence: stigma was found to erode
self-efficacy, which in turn was directly
associated with adherence
Dlamini et al. [95] Longitudinal study of 698 persons
(72.3% on ART for more than 1 year)
enrolled in a larger cohort in Lesotho,
Malawi, South Africa, Swaziland and
Tanzania
200607 33-item HIV and AIDS Stigma
Instrument-PLWA [96]
ACTG Adherence Instrument [94] Persons who did not report any missing
doses experienced a steeper decline in
mean stigma over time, after adjusting for
education, employment, food insecurity,
social support and years since diagnosis
Do et al. [97] Cross-sectional study of 300 outpatients
from the largest ART clinic in Botswana
2005 Disclosure of seropositivity to a
partner
Adherence defined as no missed doses
with four-day and one-month recall, and
no missed refill visits with 90-day recall
Non-disclosure was associated with an
increased odds of non-adherence
(pB0.02; AOR not shown), after adjusting
for education, employment, travel time,
duration of ART, depression, alcohol use
and household size
Franke et al. [98] 2-year longitudinal study of 134 adults
initiating ART in urban Peru
200509 40-item HIV stigma scale [81] 30-day self-report, with ‘‘suboptimal’’
adherence defined asB95% [94]
On univariable analysis, perceived HIV
stigma was not associated with suboptimal
adherence (OR1.03, 95% CI 0.941.12)
and was not included in the final
multivariable model
Goldman et al. [99] Longitudinal study of 913
treatment-naı¨ve adults initiating
ART in urban Zambia
200607 Disclosure of HIV status to partner or
spouse
Medication possession ratio based on
cumulative days late for pharmacy refill
visits, with]95% defined as optimal
adherence
Disclosure did not have a statistically
significant association with optimal
adherence (estimates not reported)
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Table 2 (Continued )
Citation Study design and population
Study
period
Primary stigma or
disclosure measure Primary adherence measure Findings
Kalichman et al.
[100]
Cross-sectional study of 81 adults
recruited from HIV clinical and
community support services in Atlanta
2005a 4-item self-efficacy for disclosure
decisions scale
6-item standard medication adherence
self-efficacy scale [101]
Self-efficacy for disclosure had a
statistically significant correlation with
self-efficacy for engaging in care (r0.24,
pB0.05) but not with self-efficacy for
medication adherence (r0.19, p0.05)
Kalichman et al.
[102]
Cross-sectional study of 145 adults
recruited from HIV clinical and
community support services in Atlanta
2008a 6-item Internalized AIDS-Related
Stigma Scale [103]
Monthly unannounced pill count
conducted by telephone, averaged over
four months, with adherence defined as
]85% of doses taken
Internalized stigma had no statistically
significant association with adherence
(AOR0.99, 95% CI 0.871.13)
Li et al. [104] Cross-sectional study of 386 adults
(23.9% of whom were treatment-naı¨ve),
recruited from four district hospitals
throughout Thailand
2007 8-item scale assessing serostatus
disclosure to various social ties [105]
and 9-item internalized stigma scale
[106,107]
30-day self-reported adherence, with
good adherence defined as no missed
doses
Good adherence had a statistically
significant association with disclosure
(AOR1.70; 95% CI1.072.70) but not
internalized stigma (AOR0.83; 95%
CI0.511.36), after adjusting for
education, employment, instrumental social
support, depression symptom severity,
family functioning and years since diagnosis
Li et al. [108] Cross-sectional study of 202 outpatients
enrolled in the Chinese national free
ART program, selected from six HIV
treatment sites in Hunan Province, China
2009 34-item, five-factor HIV-related
stigma scale [109]
Seven-day self-reported ART adherence as
measured on a 5-point Likert scale [110]
Stigma was associated with a reduced
odds of good adherence (AOR0.96; 95%
CI0.930.98), after adjusting for
education, family income, years since
diagnosis and recent drug use
Lucero et al. [111] Cross-sectional study of 65 persons aged
50 years recruited from two hospitals
in New York City
2001a Disclosure of HIV seropositivity to
family and friends
Self-report, rated on a 4-point Likert-type
scale, with good adherence defined as
‘‘taking medication all of the time’’
Disclosure was associated with better
adherence (estimates not shown)
Martinez et al. [112] Longitudinal study of 178 girls and
women aged 15-24 years recruited from
5 cities throughout the U.S.
200305 The disclosure concerns and negative
self-image subscales of the HIV
stigma scale [81]
12-item scale to measure self-reported
dosing and scheduling adherence with a
two-day recall
Baseline stigma did not have a statistically
significant association with complete
adherence at 12-month follow-up
(b0.012, p0.50).
Mo and Mak [113] Cross-sectional study of 102 adults
recruited from an outpatient clinic in
Hong Kong
2009a 22-item self-stigma scale [114] ACTG Adherence Instrument [94], with
participants classified as ‘‘adherers,’’
‘‘unintentional non-adherers,’’ or
‘‘intentional non-adherers’’
Intentional non-adherers had greater
self-stigma (4.11, SD 0.74) than adherers
(3.78, SD 0.96) and unintentional
non-adherers (3.22, SD 0.92)
F[1,100]7.58, pB0.001)
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Table 2 (Continued )
Citation Study design and population
Study
period
Primary stigma or
disclosure measure Primary adherence measure Findings
Molassiotis et al.
[115]
Cross sectional study of 136 adults
recruited from an outpatient clinic in
Hong Kong
2002a HIV disclosure to others, including
spouses or partners
ACTG Adherence Instrument [94], with
good adherence defined as]95%
adherence
Disclosure did not have a statistically
significant association with adherence
(estimates not shown)
Muyingo et al. [116] Secondary analysis of data from a
randomized trial of 2957
treatment-naı¨ve adults initiating ART at
two treatment centres in Uganda and
one in Zimbabwe
200304 Disclosure of HIV serostatus Drug possession ratio, with complete
adherence defined as 100% adherence
Disclosure did not have a statistically
significant association with complete
adherence (estimates not shown), after
adjusting for education and duration of
current partnership
Nachega et al. [117] Cross-sectional study of 66 outpatients
at an HIV clinic in South Africa
2002 Fear of stigma from partner ACTG Adherence Instrument [94] On univariable analysis, fear of stigma
from partner was associated with reduced
odds of 95% adherence (OR0.13; 95%
CI0.020.70)
Olowookere et al.
[118]
Cross sectional study of 318 adults on
ART for at least three months, recruited
from a university hospital HIV clinic in
Nigeria
2007 Disclosure of HIV serostatus Seven-day self-reported adherence, with
non-adherence defined asB95% doses
taken
Non-disclosure was associated with
increased odds of non-adherence
(AOR1.7; 95% CI1.02.8), after
adjusting for transportation costs
Peltzer et al. [119] Cross-sectional study of 735 adults
newly initiating ART at one of 3 public
hospitals in KwaZulu-Natal, South Africa
200708 7-item version of the AIDS-Related
Stigma Scale [120], modified to
reflect internalized stigma; 7-item
AIDS-related discrimination scale
ACTG Adherence Instrument [94] and
30-day visual analogue scale [121], with
partial or full adherence defined as ]95%
adherence
Partial or full VAS adherence was
associated with AIDS-related
discrimination (AOR0.60; 95%
CI0.460.78) but not internalized
stigma (OR1.11; 95% CI0.971.27),
after adjusting for alcohol use and social
support; use of the ACTG Adherence
Instrument yielded similar results
Penniman [122] Secondary analysis of baseline data on
259 women enrolled in a larger cohort
study in Los Angeles
200506 Disclosure of HIV serostatus to child 3-item self-reported dose-taking and
timing adherence with two-day recall
Non-disclosure was associated with
reduced odds of adherence (AOR0.46;
95% CI0.240.88), after adjusting for
stress, family functioning and depression
symptom severity
Peretti-Watel et al.
[123]
Cross-sectional study of 2932 adults
recruited from 102 hospitals in France
2003 Disclosure of HIV serostatus to friends
and family; HIV-related discrimination
by friends or family
Self-reported measure based on dose and
timing adherence with one-week recall,
with ‘‘high adherence’’ defined as no
doses missed or mistimed
Poor adherence was associated with
HIV-related discrimination (AOR1.68;
95% CI1.002.82) but not selective
disclosure to significant others
(AOR0.73; 95% CI0.281.94), after
adjustment for alcohol and drug use
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Table 2 (Continued )
Citation Study design and population
Study
period
Primary stigma or
disclosure measure Primary adherence measure Findings
Rao et al. [124] Cross-sectional study of 720 outpatients
from a university HIV clinic in Seattle
2009 Summated rating scale of 4 items
related to internalized and enacted
stigma, from the 24-item Stigma
Scale for Chronic Illness [125]
3 items from the ACTG Adherence
Instrument [94], a one-item rating
response measure [126] and a 30-day VAS
[121]
In a structural equation model, stigma was
associated with reduced adherence
(b0.21, pB0.01); the authors
concluded that the effect was mediated by
depression symptom severity
Rintamaki et al.
[127]
Cross-sectional study of 204 outpatients
at two urban academic medical centre
clinics in Illinois and Louisiana
2001 Summated rating scale of 3 items
from the Patient Medication
Adherence Questionnaire (PMAQ)
[128,129] related to internalized
stigma and disclosure concerns
Non-adherence defined as any missed
doses in the prior four days, assessed
using the PMAQ
High stigma was associated with greater
odds of non-adherence (AOR3.3;
95% CI1.48.1), after adjusting for race
& education
Rotheram-Borus
et al. [130]
Secondary analysis of baseline data from
a randomized controlled trial of 409
adults recruited from 4 district hospitals
in northern Thailand
2009a 7-item summative rating scale
assessing extent of HIV serostatus
disclosure to social network ties
Self-reported lifetime adherence, with
good adherence defined as never having
missed a dose
Disclosure had a statistically significant
association with adherence (b0.11,
pB0.05); the authors concluded that
disclosure operates primarily through its
effect on family functioning
Rougemont et al.
[131]
Longitudinal study of 312
treatment-naı¨ve adults initiating ART in
Yaounde´, Cameroun
200607 Disclosure of HIV serostatus to family Pharmacy refill, with ‘‘non-adherers’’
defined as ‘‘renewal of prescriptions of
later than two weeks’’
Non-disclosure did not have a statistically
significant association with non-adherence
(AOR0.98; 95% CI0.811.18), after
adjustment for income, education and
distance to clinic
Sayles et al. [132] Cross-sectional study of 202 adults
recruited from 5 community
organizations and 2 HIV clinic sites in Los
Angeles
2007 28-item internalized stigma scale
[133]
Seven-day self-reported ART adherence as
measured on a 5-point Likert scale [110],
with suboptimal adherence as defined as
any response other than ‘‘all of the time’’
A high level of internalized stigma was not
associated with suboptimal adherence
(AOR2.09; 95% CI0.815.39), after
adjusting for mental health, race,
education, income, insurance and years
since diagnosis
Spire et al. [134] Longitudinal study of 445
treatment-naı¨ve adults initiating ART,
recruited from 47 hospitals across
France
1997 Disclosure of HIV serostatus to a
family member
Self-reported adherence over prior four
days, with ‘‘adherent’’ defined as 100%
adherence
71% of participants who had disclosed to a
family member at baseline were classified
as adherent four months later, compared
to 76% of those who had not disclosed
(p0.26)
Stirratt et al. [135] Cross-sectional study of 215 adults
recruited from 2 outpatient HIV clinics in
New York City
200004 Disclosure of HIV serostatus to up to
15 family members and 15 personal
contacts [136]
14-day ART adherence as measured by
electronic event monitoring
Percentage of informed family members
had a statistically significant association
with ART adherence (b0.21, pB0.05)
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Table 2 (Continued )
Citation Study design and population
Study
period
Primary stigma or
disclosure measure Primary adherence measure Findings
after adjusting for self-efficacy, motivation
and outcome expectancies
Sumari-de Boer
et al. [137]
Cross-sectional study of 201 outpatients
at an academic medical centre HIV clinic
in Amsterdam, the Netherlands
200809 Personalized stigma and disclosure
concerns sub-scales of the HIV stigma
scale [81]
30-day pharmacy refill adherence, with
non-adherence defined asB100%
adherence
Non-adherence had a statistically
significant association with disclosure
concerns (AOR1.1; 95% CI1.011.2)
but not personalized stigma (AOR not
reported), after adjusting for years since
diagnosis, quality of life and depression
symptom severity
Van Dyk [138] Cross-sectional study of 439 adults
recruited from public health HIV clinics
and hospitals in Pretoria, South Africa
2008 Disclosure of HIV serostatus to
partner
30-day self-reported adherence as elicited
through a visual assessment scale [121],
with optimum adherence defined as
90% adherence
41% of participants who had disclosed to
partners reported optimum adherence,
compared to 21% of participants who had
not disclosed (p0.006)
Vanable et al. [139] Cross sectional study of 221 outpatients
in central New York state
2001 Five-item frequency of stigma-related
experiences scale
Summary self-reported adherence
measure averaged across 4 items based
on a seven-day recall period
Stigma-related experiences had a negative
association with self-reported adherence
(b0.20, pB0.01), after adjusting for
income, employment status and time since
diagnosis
Waite et al. [140] Cross-sectional study of 204 outpatients
at two urban academic medical centre
clinics in Illinois and Louisiana
2001 Summated rating scale of 3 items
from the Patient Medication
Adherence Questionnaire (PMAQ)
[128,129] related to internalized
stigma and disclosure concerns
Non-adherence defined as any missed
doses in the prior four days, assessed
using a modified version of the PMAQ
A high level of stigma was associated with
increased odds of non-adherence
(AOR3.1; 95% CI1.37.7), after
adjusting for insurance coverage,
employment, mental disorder and
history of alcohol or drug
treatment
Wang et al. [141] Cross-sectional study of 308 adults
recruited from seven treatment sites in
China
2006 Disclosure of HIV serostatus Seven-day self-reported adherence, with
good adherence defined as90% of
doses taken
Disclosure did not have a statistically
significant association with adherence
(estimates not shown)
Watt [142] Cross sectional study of 340 persons in
Tanzania
2007a 10-item perceived stigma scale [143],
and number of social network ties to
whom the participant had disclosed
his or her seropositivity
Self-reported missed doses in the prior
four days [94], and 30-day self-reported
adherence using a modified visual
analogue scale [121], with optimal
adherence defined as]95% adherence
on both instruments
On univariable analysis, neither stigma nor
disclosure had statistically significant
associations with optimal adherence
(estimates not shown)
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Trials Group measure developed by Chesney et al. [94] was
the most frequently used among these (10/16 (63%)).
Among the 41 studies, 25 (61%) reported a positive finding
(i.e., showing that stigma was associated with reduced ART
adherence or that disclosure was associated with improved
adherence) while 16 (39%) reported a null finding. No studies
reported that better ART adherence was paradoxically asso-
ciated with greater intensity of stigma or less disclosure.
A roughly equal proportion of studies conducted outside
of the United States reported a positive finding compared
to US-based studies (16/26 (62%) vs. 9/15 (60%); Pearson’s
x20.01, p0.92).
When the studies were disaggregated by study design,
most of the cross-sectional studies (24/34 (71%)) reported a
positive finding, while most of the longitudinal studies (6/7
(86%)) reported a null finding (Pearson’s x27.7; p0.005).
When disaggregated by exposure, these differences were
slightly attenuated. Among studies examining the impact of a
stigma variable on adherence, 15/20 (75%) cross-sectional
studies vs. 1/3 (33%) longitudinal studies reported a positive
finding (Pearson’s x22.14; p0.14). Among studies ex-
amining the impact of disclosure on adherence, 11/17 (65%)
cross-sectional studies vs. 0/4 (0%) longitudinal studies
reported a positive finding (Pearson’s x25.4; p0.02).
In three cross-sectional studies, the authors fit structural
equation models to investigate the relationships between
study variables. Diiorio et al. [92] concluded that the asso-
ciation between stigma and ART adherence was mediated by
self-efficacy: perceived stigma eroded one’s confidence about
adhering to a treatment regimen, which in turn undermined
treatment adherence. Rao et al. [124] did not measure self-
efficacy but concluded that internalized stigma worsened
symptoms of depression, like fatigue and concentration
difficulties, which in turn compromised one’s ability to
adhere to a complex treatment regimen. In the study by
Rotheram-Borus et al. [130], disclosure had a statistically
significant association with ART adherence; the authors
concluded that the effect was mediated principally by
improvements in family function.
Conceptual model
To integrate our core findings from the qualitative and
quantitative studies, we propose a conceptual model de-
scribed in Figure 3, citing areas of congruence between our
empirically derived themes and theoretical frameworks
previously published by others. In our model, structural
and economic barriers associated with poverty undermine
ART adherence. Enacted stigma undermines ART adherence
through psychological processes specific to HIV-positive
persons as well as through general psychological processes
that are common to HIV-positive and HIV-negative persons
alike. Stigma and poverty have mutually reinforcing relation-
ships with each other, particularly in resource-limited settings
[146]: stigma and social isolation have adverse economic
impacts and, conversely, poverty worsens stigma by high-
lighting the economic aspects of HIV’s perceived association
with premature morbidity and mortality.
Internalized stigma may result when HIV-positive persons
accept as valid the stigmatizing beliefs of the majority group.Ta
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Because HIV infection is a potentially concealable stigma,
HIV-positive persons may attempt to delay disclosure until
disease progression renders further concealment impossible
[147]. As elaborated in the stress process model [148,149]
and as described by the participants in the studies summari-
zed in this review, HIV-positive persons draw on adaptive
coping and social support to minimize the harmful effects of
life stressors.
Adaptive coping and social support partially moderate the
harmful effects of poverty on adherence and are represented
in the diagram as effect modifiers: in the presence of adap-
tive coping or strong social support networks, the negative
impacts of poverty on adherence are reduced. In this regard
our synthesis is consistent with the social support model
described by Ware et al. [150], who found that HIV-positive
persons in Nigeria, Tanzania and Uganda relied heavily on
social support to overcome structural and economic barriers
to care. The authors concluded that the stigma of HIV
was feared specifically because it weakened relationships
that proved to be critical for everyday survival. In addition,
as supported by both the qualitative and the quantitative
studies summarized in this review, these general and group-
specific psychological processes can directly benefit or
undermine ART adherence. For example, in the setting
of enacted stigma, many HIV-positive participants adopted
strategies of concealment, which led directly to treatment
interruptions.
The qualitative studies we identified also suggested a
number of extensions to the model, namely that certain
factors can moderate the severity of enacted stigma and
their ultimate impacts on ART adherence. One such factor
is the health system, which can be configured to support
patients and minimize the harmful influences of stigma on
ART adherence. Although resistance to stigma has been
described [151], in countries with fragile healthcare systems
resistance to stigma can be weakened as HIV-positive persons
struggle with the anxieties of uncertain and unstable access
to treatment [80]. Another factor involves social norms,
which were described by participants in the qualitative
studies as potentially intensifying the harmful influences
of stigma. HIV-positive persons who belonged to sexual
minority groups or who had acquired HIV through socially
unacceptable means, in particular, experienced greater
stigma because their self-identities and behaviours were
defined by the majority as being inconsistent with social
norms.
Discussion
In this systematic review of both qualitative and quantitative
studies conducted among 26,715 HIV-positive persons living
in 32 countries worldwide, we found that HIV-related stigma
compromised ART adherence, primarily by undermining
social support and adaptive coping. Our analysis is consistent
with prior work demonstrating the importance of social
ties in promoting adherence, particularly in resource-limited
settings [33,152], and reflects the centrality of social in-
tegration to the experience of HIV-positive persons engaged
in treatment. These themes are all the more prominent in
settings of extreme poverty where treatment barriers are
highly prevalent [8,14,153] and where social ties may be
essential for survival [72,154,155]. Our findings have implica-
tions for public health strategies now being explored in
high-HIV prevalence regions, such as universal voluntary
testing with immediate treatment [36]. The evidence search
protocol was not designed to identify studies examining
the influences of stigma on HIV testing [156,157], pre-
ART linkage to care [158,159], ART refusal [160], or other
treatment- and care-related behaviours along the entire
continuum of engagement in care [35]. However, HIV-related
stigma has been shown to adversely affect these treatment-
and care-related behaviours in a wide range of settings
[35,161166]. Optimization of the entire continuum of care
Poverty Adherence
General:
Adapve
Coping & Social
Support  
Group-Specific:
Internalized
Sgma &
Concealment  
Enacted 
Sgma
Moderators:
Health Systems
Social Norms
Figure 3. Conceptual model. This figure summarizes the findings of our meta-synthesis of 34 qualitative studies and analysis of
41 quantitative studies. The stigma of HIV was found to compromise ART adherence through general as well as group-specific psychological
processes. Adaptive coping and social support were critical determinants of participants’ ability to overcome structural and economic barriers
associated with poverty to successfully adhere to ART.
Katz IT et al. Journal of the International AIDS Society 2013, 16(Suppl 2):18640
http://www.jiasociety.org/index.php/jias/article/view/18640 | http://dx.doi.org/10.7448/IAS.16.3.18640
19
is needed to maximize the public health impact of test-
and-treat [34], thereby underscoring the importance of our
findings.
Several limitations are important to consider when asses-
sing this systematic review. First, it is well known that
qualitative studies can be difficult to locate using con-
ventional search strategies [167]. Although we adopted a
purposefully broad search protocol that involved the full text
review of 960 journal articles, unpublished dissertations and
conference abstracts, we cannot exclude the possibility that
we may have missed some relevant studies. Second, and
related to the previous, we only identified one (qualitative)
study from the UNAIDS Eastern Europe and Central Asia
region. The HIV epidemic follows a different pattern in these
countries, with concentrated epidemics most notably driven
by injection drug use but also by prison overcrowding and
unprotected sexual intercourse among men who have sex
with men and sex workers [168170]. For people belonging
to these already marginalized subgroups, the stigma of their
HIV serostatus is layered upon these pre-existing inequalities,
thereby displacing them further downward in the status
hierarchy. If we had been able to identify more studies from
this region, it is possible that different themes could have
been identified in the qualitative synthesis or that an even
stronger association between stigma and ART adherence
would have been described. Third, heterogeneity in the types
of exposures and outcomes used in the quantitative studies
precluded a formal meta-analysis. The vote counting-styled
procedures we employed to synthesize their findings could
not generate effect size estimates, are characterized by low
statistical power [171] and cannot assess the magnitude of
the purported relationship. As the field converges on the use
of standardized and validated measures of stigma, disclosure
and adherence, we expect that the methods of meta-analysis
can be increasingly applied. Fourth, a greater proportion of
longitudinal studies reported a null association between ART
adherence and either stigma or disclosure. The difference
appeared to be driven by studies examining the impact
of disclosure on adherence. The single longitudinal study
that documented a positive finding employed validated
instruments to measure both stigma and self-reported
ART adherence, but in general the relatively small number
of longitudinal studies limited our ability to draw strong
conclusions. Fifth, the majority of studies included in this
review were assessed to be at risk of bias. A key reporting
deficiency in the qualitative studies was lack of detail on the
method of analysis. The majority of quantitative studies did
not use validated exposure and outcome measures. Although
these factors could exert unpredictable biases, we acknowl-
edge they could have biased the qualitative and quantitative
findings towards the null, with attendant effects on our
conceptual model.
These caveats aside, the conceptual model that emerged
from our synthesis of the literature has several important
implications for programming and policy. At the individual
level, interventions focused on enhancing social support by
activating [172] or strengthening existing ties [173,174], or
facilitating either of these through the encouragement of
serostatus disclosure [175177], may be expected to improve
ART adherence. These behaviours may in turn yield health
and mental health dividends. Although our meta-synthesis
highlighted positive self-identity as an important factor
related to greater adherence, more research is needed to
understand the conditions under which HIV-related out-
comes are better than expected despite the experiences of
HIV- and stigma-related adversity (which can be thought of as
being related to the concept of resilience [178180]). It
should be acknowledged here that social ties are not
uniformly beneficial. This was observed in our data showing
that all relationships were not necessarily described as
supportive and that some study participants’ experiences
suggested positive benefits from concealment. There have
been few intervention studies where disclosure was empha-
sized as a primary outcome [181], but the outcomes of HIV
serostatus disclosure are not unambiguously positive. Due to
HIV-related stigma, significant others may react in nega-
tive ways after learning about a loved one’s seropositivity
[182184]. In order to avoid these undesirable outcomes,
interventions targeting disclosure behaviours should be
sensitive to these potential negative consequences.
At the structural level, our model suggests that structural
interventions (which target the context in which people live,
including social ties, resources and institutions [185]) to
enhance the capacity of health systems for providing quality
care may help to minimize the adverse effects of HIV-related
stigma on ART adherence. Structural interventions that
strengthen the livelihoods of HIV-positive persons may also
be a promising avenue for subverting HIV-related stigma,
particularly in resource-limited settings where contributing to
local solidarity networks is a core social function [186] and
where the economic impacts of HIV and AIDS have exacer-
bated both the instrumental and symbolic aspects of stigma
attached to HIV [187]. Castro and Farmer [188] advanced the
argument that ‘‘structural violence determines, in large part,
who suffers from AIDS-related stigma and discrimination’’
(p. 55). Although some observers have speculated that
economic strengthening or livelihood interventions may
play a role in reducing HIV-related stigma [146], to our
knowledge these hypotheses have not been formally tested
[189,190]. Related work suggests that these may spark a
‘‘virtuous’’ cycle: as stigma-related barriers are levelled and
as HIV testing, treatment and other care-related behaviours
become more widespread, the stigma of HIV and AIDS can be
reduced [188,191195].
Notably, our conceptual model also suggests several pro-
mising points of intervention to improve ART adherence that
have not consistently yielded benefits when tested for their
impacts on ART adherence. For example, several studies
described how effective treatment of depression could
potentially improve treatment adherence, consistent with
the positive prevention model elaborated by Sikkema et al.
[196]. However, depression intervention studies have yielded
mixed findings to date with regards to HIV treatment
adherence outcomes [197199]. Likewise social support
interventions should also be expected to improve adherence,
but these have also proved inconclusive [200203]. The lack of
consistent findings may potentially be explained by the fact
that interventions targeting intrapersonal or interpersonal
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processes fail to address the larger social forces undermining
adherence to HIV treatment. We emphasize here that the
concepts embedded in our conceptual model span multiple
levels of analysis [204,205], ranging from intrapersonal
processes (self-identity, coping), to interpersonal processes
(social support, concealment), to structural factors (health
systems, poverty, stigma). We therefore expect that inter-
ventions spanning multiple levels would yield the greatest
impacts on reducing stigma [206], but these approaches have
been rarely employed.
Conclusions
In this review of both qualitative and quantitative studies, we
found that HIV-related stigma compromises ART adherence
through general as well as group-specific psychological
processes. Adaptive coping and social support were critical
determinants of participants’ ability to overcome structural
and economic barriers associated with poverty to success-
fully adhere to ART. Our conceptual model, which integrates
the results of both quantitative and qualitative studies,
suggests that the effects of stigma operate at multiple levels
(intrapersonal, interpersonal and structural). Interventions
to reduce stigma should target these multiple levels of
influence in order to have maximum effectiveness on
improving ART adherence.
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